IGF-1 as a Blood Marker: What It Tells You About the GH Axis Before and During a Peptide Protocol

Insulin-like growth factor 1 (IGF-1) is the most widely used blood readout of the growth hormone axis. This article explains what it reflects, what can distort it, and why it is interpreted alongside the clinical picture rather than in isolation.

By UAE Peptide Clinic Research Desk

Growth hormone is released in short pulses, mostly overnight, and is cleared from the blood within minutes. A single GH measurement therefore tells a clinician very little. Insulin-like growth factor 1 (IGF-1) is the practical alternative: a protein made largely in the liver in response to GH, which circulates at far more stable levels and gives a time-averaged picture of the axis. For anyone considering a GH-axis peptide protocol, it is usually one of the first markers reviewed.

What IGF-1 actually reflects

When GH reaches the liver, it stimulates production of IGF-1, which then travels bound to a family of carrier proteins, chiefly IGFBP-3. This binding extends its half-life from minutes to many hours, which is why a morning blood draw is representative of the preceding days rather than the preceding hour. Research suggests IGF-1 correlates reasonably well with integrated GH secretion in healthy adults, although the relationship is not perfectly linear.

IGF-1 also declines with age. Population data show levels peaking in adolescence and falling steadily through adulthood, which is one reason results are compared against age- and sex-specific reference ranges rather than a single universal number.

IGF-1 is a window onto the GH axis, not a verdict on it. The number only means something once the context around it is understood.

Why a single result can mislead

Several factors move IGF-1 independently of how well the pituitary is functioning. A clinician reviewing a result will usually consider:

  • Nutrition: low protein or energy intake, prolonged fasting and significant calorie restriction can lower IGF-1 even when GH secretion is intact.
  • Liver function: because the liver produces most circulating IGF-1, hepatic disease can depress levels.
  • Thyroid status: untreated hypothyroidism is associated with lower IGF-1 in the literature.
  • Glucose and insulin: poorly controlled diabetes and insulin resistance can alter the relationship between GH and IGF-1.
  • Oral oestrogen: oral contraceptives and oral hormone therapy are known to reduce hepatic IGF-1 output, while transdermal routes have less effect.
  • Acute illness, inflammation and recent intense training: all can shift a single reading.

For this reason, IGF-1 is best read alongside a broader panel, including fasting glucose or HbA1c, thyroid function, liver enzymes and inflammatory markers, rather than treated as a stand-alone target.

Baseline, monitoring and the question of upper limits

A baseline IGF-1 taken before a protocol begins provides the reference point against which later results are judged. Repeat testing after several weeks allows the clinical team to see whether the axis is responding and whether levels are staying within a sensible range for the person's age and sex. Timing matters: results are most comparable when blood is drawn under similar conditions, ideally fasted and not immediately after hard training.

There is also a reason to look at the upper end of the range. Observational research has linked persistently high IGF-1 with certain adverse outcomes, and the signalling pathway influences cell growth in general. Higher is not automatically better, and clinicians typically aim to keep levels within the physiological range for the individual rather than pushing towards the ceiling.

Clinical nuance: low IGF-1 is not a diagnosis

A low-normal or modestly low result does not on its own indicate GH deficiency. Formal diagnosis of GH deficiency in adults involves dynamic stimulation testing under specialist supervision, and the cause of a low reading, whether dietary, hepatic, endocrine or age-related, needs to be understood first. Equally, a result that is unexpectedly high warrants a review of medications, supplements and any other source of growth-factor activity before any protocol decisions are made.

Whether any protocol is appropriate is a decision for an independent DHA-licensed physician. Read more on the IGF-1 LR3 page.

This content is educational and does not constitute medical advice. If you're exploring IGF-1 testing as part of your protocol, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.

UAE Peptide Clinic